Skip to main content
. 2014 Dec 17;4(2):113–122. doi: 10.4161/21623945.2014.973772

Figure 1.

Figure 1.

Positive effects of 5-year GH replacement therapy on the whole-body and adipose tissue metabolic phenotypes. The effect of 5-year GH replacement therapy on (A) glucose tolerance (2h glycemia in oral glucose tolerance test), (B) adipose tissue insulin sensitivity (ability of insulin to suppress FFA during EHC) and (C) adipocyte size (lines connect the data points of the “real follow-up” patients). Associations of adipose tissue ZAG gene expression with the (D) whole-body and (E) adipose tissue insulin sensitivity (ability of insulin to suppress FFA during EHC) and (F) adipocyte size (Δ controls; ○ baseline GH naive patients; GH treated GHD patients). GHD, patients with growth hormone deficiency; EHC, euglycemic hyperinsulinemic clamp; FFA, free fatty acids; ZAG, zinc-α2-glycoprotein; rhGH, recombinant human growth hormone; *P < 0.05; **P < 0.01; ***P < 0.001.